SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Françoise Kraeber-Bodéré, Jacques Barbet, Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine, Frontiers in Medicine, 2014, 1,

    CrossRef

  2. 2
    Mohamed E. El-Zaria, Afaf R. Genady, Nancy Janzen, Christina I. Petlura, Denis R. Beckford Vera, John F. Valliant, Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA), Dalton Transactions, 2014, 43, 13, 4950

    CrossRef

  3. 3
    Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, Thomas Eugène, Amandine Pallardy, Eric Frampas, Thomas Carlier, Ludovic Ferrer, Joëlle Gaschet, François Davodeau, Alain Faivre-Chauvet, Michel Chérel, Jacques Barbet, Radioimmunoconjugates for the treatment of cancer, Seminars in Oncology, 2014,

    CrossRef

  4. 4
    Christof Seidl, Radioimmunotherapy with α-particle-emitting radionuclides, Immunotherapy, 2014, 6, 4, 431

    CrossRef

  5. 5
    Sophie E. Eriksson, Erika Elgström, Tom Bäck, Tomas Ohlsson, Holger Jensen, Rune Nilsson, Sture Lindegren, Jan Tennvall, Sequential Radioimmunotherapy with177Lu- and211At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model, Cancer Biotherapy & Radiopharmaceuticals, 2014, 29, 6, 238

    CrossRef

  6. 6
    Susan F. Slovin, Marissa Kehoe, Robert Durso, Celina Fernandez, William Olson, Jian P. Gao, Robert Israel, Howard I. Scher, Stephen Morris, A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer, Vaccine, 2013, 31, 6, 943

    CrossRef

  7. 7
    Olcay Boyacioglu, Christopher H Stuart, George Kulik, William H Gmeiner, Dimeric DNA Aptamer Complexes for High-capacity–targeted Drug Delivery Using pH-sensitive Covalent Linkages, Molecular Therapy—Nucleic Acids, 2013, 2, 7, e107

    CrossRef

  8. 8
    Jesal C. Patel, Benjamin L. Maughan, Archana M. Agarwal, Julia A. Batten, Tian Y. Zhang, Neeraj Agarwal, Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer, Prostate Cancer, 2013, 2013, 1

    CrossRef

  9. 9
    Alcides Chaux, John Eifler, Sarah Karram, Turki Al-Hussain, Sheila Faraj, Martin Pomper, Ronald Rodriguez, George J. Netto, Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 5, 572

    CrossRef

  10. 10
    Raymond A Clarke, Barry J Allen, Next-generation therapy for residual prostate cancer, Immunotherapy, 2013, 5, 11, 1235

    CrossRef

  11. 11
    Joseph R. Osborne, Naveed H. Akhtar, Shankar Vallabhajosula, Alok Anand, Kofi Deh, Scott T. Tagawa, Prostate-specific membrane antigen-based imaging, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 2, 144

    CrossRef

  12. 12
    Naveed H Akhtar, Joseph R Osborne, Shoaib B Fareedy, Scott T Tagawa, PSMA-targeted dendrimers: a patent evaluation (WO2012078534), Expert Opinion on Therapeutic Patents, 2013, 23, 5, 665

    CrossRef

  13. 13
    Emmanuel S. Antonarakis, Charles G. Drake, Combining immunological and androgen-directed approaches, Current Opinion in Oncology, 2012, 24, 3, 258

    CrossRef

  14. 14
    Charles G. Drake, Emmanuel S. Antonarakis, Current status of immunological approaches for the treatment of prostate cancer, Current Opinion in Urology, 2012, 22, 3, 197

    CrossRef

  15. 15
    M. Lacombe, L. Ferrer, S. Supiot, M. Bardiès, F. Davodeau, A. Faivre-Chauvet, P. Baumgartner, J. Wijdenes, J. Barbet, T. Guillaume, P. Moreau, J.-L. Harousseau, F. Kraeber-Bodéré, M. Cherel, C. Rousseau, Étude clinique de phase I avec bénéfice individuel direct de radioimmunothérapie du myélome multiple utilisant l’anticorps anti-CD138 marqué à l’iode 131 (131I-B-B4), Médecine Nucléaire, 2012, 36, 2, 83

    CrossRef

  16. 16
    Michael C Haffner, Johannes Laimer, Alcides Chaux, Georg Schäfer, Peter Obrist, Andrea Brunner, Irmgard E Kronberger, Klaus Laimer, Bora Gurel, Johann-Benedikt Koller, Christof Seifarth, Bettina Zelger, Helmut Klocker, Michael Rasse, Wolfgang Doppler, Neil H Bander, High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity, Modern Pathology, 2012, 25, 8, 1079

    CrossRef

  17. 17
    James P. Smith, Alexander C. Barbati, Steven M. Santana, Jason P. Gleghorn, Brian J. Kirby, Microfluidic transport in microdevices for rare cell capture, ELECTROPHORESIS, 2012, 33, 21
  18. 18
    Yoko Hasegawa, Nobuyuki Oyama, Keiko Nagase, Yasuhisa Fujibayashi, Takako Furukawa, Yasuko Murayama, Yoichi Arai, Seiichi Saito, Michael J. Welch, Osamu Yokoyama, Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging, Nuclear Medicine and Biology, 2012, 39, 7, 944

    CrossRef

  19. 19
    Neeraj Agarwal, Guru Sonpavde, Cora N. Sternberg, Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer, European Urology, 2012, 61, 5, 950

    CrossRef

  20. 20
    Daniel J. Lee, Eugene K. Cha, Justin M. Dubin, Himisha Beltran, Thomas F. Chromecki, Harun Fajkovic, Douglas S. Scherr, Scott T. Tagawa, Shahrokh F. Shariat, Novel therapeutics for the management of castration-resistant prostate cancer (CRPC), BJU International, 2012, 109, 7
  21. 21
    Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, Scott T. Tagawa, Prostate-Specific Membrane Antigen-Based Therapeutics, Advances in Urology, 2012, 2012, 1

    CrossRef

  22. 22
    Satyajit Kosuri, Naveed H. Akhtar, Michael Smith, Joseph R. Osborne, Scott T. Tagawa, Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy, Advances in Urology, 2012, 2012, 1

    CrossRef

  23. 23
    Sophie E. Eriksson, Tomas Ohlsson, Rune Nilsson, Jan Tennvall, Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with177Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model, Cancer Biotherapy & Radiopharmaceuticals, 2012, 27, 3, 175

    CrossRef

  24. 24
    Robert M Sharkey, David M Goldenberg, Cancer radioimmunotherapy, Immunotherapy, 2011, 3, 3, 349

    CrossRef

  25. 25
    Giuseppe Di Lorenzo, Carlo Buonerba, Philip W. Kantoff, Immunotherapy for the treatment of prostate cancer, Nature Reviews Clinical Oncology, 2011, 8, 9, 551

    CrossRef

  26. You have free access to this content26
    Sujitra Detchokul, Albert G. Frauman, Recent developments in prostate cancer biomarker research: therapeutic implications, British Journal of Clinical Pharmacology, 2011, 71, 2
  27. 27
    Neeraj Agarwal, Nicholas Vogelzang, Cancer Vaccines, 2011,

    CrossRef

  28. 28
    Neeraj Agarwal, Nicholas J. Vogelzang, Cancer Vaccines: From Research to Clinical Practice, 2011,

    CrossRef

  29. 29
    Tiancheng Liu, Lisa Y. Wu, Mark R. Hopkins, Joseph K. Choi, Clifford E. Berkman, A targeted low molecular weight near-infrared fluorescent probe for prostate cancer, Bioorganic & Medicinal Chemistry Letters, 2010, 20, 23, 7124

    CrossRef

  30. 30
    Christoph Roesli, Dario Neri, Methods for the identification of vascular markers in health and disease: From the bench to the clinic, Journal of Proteomics, 2010, 73, 11, 2219

    CrossRef

  31. 31
    Charles G. Drake, Prostate cancer as a model for tumour immunotherapy, Nature Reviews Immunology, 2010, 10, 8, 580

    CrossRef

  32. 32
    Anna M. Wu, Antibodies for the Delivery of Radionuclides,